Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD Voorraadrapport

Marktkapitalisatie: US$669.3m

Ironwood Pharmaceuticals Toekomstige groei

Future criteriumcontroles 3/6

Ironwood Pharmaceuticals is forecast to grow earnings and revenue by 45.8% and 5.8% per annum respectively while EPS is expected to grow by 82.8% per annum.

Belangrijke informatie

45.8%

Groei van de winst

82.8%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei5.8%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19
Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18
An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Winst- en omzetgroeiprognoses

NasdaqGS:IRWD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202638560N/A3034
12/31/2025359341161446
12/31/2024357171341416
6/30/20244019146147N/A
3/31/2024414-1,052148148N/A
12/31/2023443-1,002183183N/A
9/30/2023432-952227227N/A
6/30/2023427-917263263N/A
3/31/2023417182290290N/A
12/31/2022411175274274N/A
9/30/2022421168259259N/A
6/30/2022416173265265N/A
3/31/2022422527252252N/A
12/31/2021414528262262N/A
9/30/2021413530249249N/A
6/30/2021413509227227N/A
3/31/2021398143199199N/A
12/31/2020390106167169N/A
9/30/2020399111140145N/A
6/30/202042797118126N/A
3/31/2020440848897N/A
12/31/201942859411N/A
9/30/201943319-12-8N/A
6/30/2019367-153-69-69N/A
3/31/2019346-173-81-82N/A
12/31/2018347-194-71-71N/A
9/30/2018310-190-90-89N/A
6/30/2018331-71-98-94N/A
3/31/2018315-108N/A-104N/A
12/31/2017298-55N/A-101N/A
9/30/2017292-143N/A-110N/A
6/30/2017271-143N/A-80N/A
3/31/2017260-121N/A-53N/A
12/31/2016274-82N/A-26N/A
9/30/2016240-82N/A-26N/A
6/30/2016213-96N/A-52N/A
3/31/2016187-123N/A-71N/A
12/31/2015150-143N/A-107N/A
9/30/2015134-166N/A-110N/A
6/30/2015112-161N/A-123N/A
3/31/201591-173N/A-133N/A
12/31/201476-190N/A-156N/A
9/30/201443-204N/A-175N/A
6/30/201431-224N/A-194N/A
3/31/201434-229N/A-238N/A
12/31/201323-273N/A-273N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: IRWD's forecast earnings growth (45.8% per year) is above the savings rate (2.5%).

Winst versus markt: IRWD's earnings (45.8% per year) are forecast to grow faster than the US market (15.4% per year).

Hoge groeiwinsten: IRWD's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: IRWD's revenue (5.8% per year) is forecast to grow slower than the US market (8.9% per year).

Hoge groei-inkomsten: IRWD's revenue (5.8% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if IRWD's Return on Equity is forecast to be high in 3 years time

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y